Annual report
4548.TEDINET S100YDGT
Period2025-04-01 → 2026-03-31
Filed2026-06-18
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥36.6bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥39.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥36.2bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥33.5bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥34.9bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | −¥660m | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥1.3bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥1.7bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.9bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.7bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.1bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.4bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.5bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥1.9bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.5bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.2bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.2bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.2bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.7bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.5bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥1.2bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥86.3bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥83.9bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥81.8bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥75.6bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥75.2bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥11.0bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥10.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥75.3bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥73.2bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥72.3bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥67.2bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥66.3bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥8.9bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥15.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥12.1bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥25.8bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥23.4bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥1.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥513m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.6bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.2bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥3.5bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.2bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥3.4bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥870m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥1.7bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.5bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.2bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.2bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥26.99 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.25 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.08 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.49 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.32 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,379.03 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,340.98 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,324.82 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,232.41 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,179.46 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 87.2% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.3% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.4% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.9% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.2% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 2.0% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 1.7% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.1% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.3% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,142 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 1,075 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 988 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 976 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 937 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥23.6bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥26.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥25.1bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥22.1bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥25.2bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | −¥1.9bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥440m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥589m | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.3bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.8bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.8bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.7bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥419m | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.3bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥737m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥922m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥2.5bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.8bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.5bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥67.4bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥66.5bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥66.7bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥63.1bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥64.6bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥7.3bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥7.2bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥60.1bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥59.3bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥60.3bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥56.7bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥58.0bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥3.2bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥10.4bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥13.5 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥16.9 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.5 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥32.55 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.34 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥30 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥26 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥26 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,100.14 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,085.96 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,105.46 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,039.07 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,031.37 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 89.2% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.1% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.4% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.9% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.7% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.2% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.5% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.3% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.1% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.3% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 56,814,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,814,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,814,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,814,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,814,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 694 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 647 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 565 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 540 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 531 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| LALreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥680m |
| LALreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥576m |
| LALreportable segment | employees | at 2026-03-31 | 307 pure |
| LALreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥12.2bn |
| LALreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥12.2bn |
| LALreportable segment | segment assets | at 2026-03-31 | ¥16.9bn |
| LALreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥975m |
| Pharmaceuticalreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥5.5bn |
| Pharmaceuticalreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥1.4bn |
| Pharmaceuticalreportable segment | employees | at 2026-03-31 | 706 pure |
| Pharmaceuticalreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥24.5bn |
| Pharmaceuticalreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥24.5bn |
| Pharmaceuticalreportable segment | segment assets | at 2026-03-31 | ¥69.5bn |
| Pharmaceuticalreportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥1.6bn |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥6.2bn |
| —segment total | depreciation | 2025-04-01 → 2026-03-31 | ¥2.0bn |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥36.6bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥36.6bn |
| —segment total | segment assets | at 2026-03-31 | ¥86.3bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | −¥660m |
| LALreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥973m |
| LALreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥540m |
| LALreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥11.9bn |
| LALreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥11.9bn |
| LALreportable segment | segment assets | at 2025-03-31 | ¥15.9bn |
| LALreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥809m |
| Pharmaceuticalreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥3.4bn |
| Pharmaceuticalreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| Pharmaceuticalreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥27.5bn |
| Pharmaceuticalreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥27.5bn |
| Pharmaceuticalreportable segment | segment assets | at 2025-03-31 | ¥68.0bn |
| Pharmaceuticalreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥523m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥4.3bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥39.4bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥39.4bn |
| —segment total | segment assets | at 2025-03-31 | ¥83.9bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| LALreportable segment | employees | at 2026-03-31 | 15 pure |
| Pharmaceuticalreportable segment | employees | at 2026-03-31 | 550 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,596
| Item | Context | Value | Unit |
|---|---|---|---|
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00970-000HayashiHidekiMember | 1964-03-15 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E00970-000HayashiHidekiMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00970-000HayashiHidekiMember | Original text (Japanese)(注)５ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00970-000MatsuoShinkichiMember | Original text (Japanese)監査役 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00970-000MatsuoShinkichiMember | Original text (Japanese)松尾 信吉 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00970-000MatsuoShinkichiMember | 1969-01-09 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E00970-000MatsuoShinkichiMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00970-000MatsuoShinkichiMember | Original text (Japanese)(注)６ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00970-000MaruyamaTakayukiMember | Original text (Japanese)監査役 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00970-000MaruyamaTakayukiMember | Original text (Japanese)丸山 貴之 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00970-000MaruyamaTakayukiMember | 1974-08-22 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E00970-000MaruyamaTakayukiMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00970-000MaruyamaTakayukiMember | Original text (Japanese)(注)６ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00970-000MitaniWakakoMember | Original text (Japanese)監査役 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00970-000MitaniWakakoMember | Original text (Japanese)三谷 和歌子 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00970-000MitaniWakakoMember | 1974-01-04 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E00970-000MitaniWakakoMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E00970-000MitaniWakakoMember | Original text (Japanese)(注)６ | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row4Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row5Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row6Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row7Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row8Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row9Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)科研製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)医薬品事業の販売委託先として関係を強化するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)参天製薬㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)医薬品事業の販売委託先として関係を強化するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)丸全昭和運輸㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)当社製品の物流をより円滑化するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)みずほリース㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)財務面での取引関係を強化するため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)㈱テクノ菱和 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)当社の設備調達における取引関係等を円滑にするため | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)有 | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Name of securities investment equity securities reclassified from held for purposes other than pure investment to held for pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)㈱三菱ＵＦＪフィナンシャル・グループ |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |